HIV-1 viral load testing: Methods and clinical applications

Laboratory Medicine

Volumn 32, Issue 3, 2001, Pages 142-152

  Ginocchio, C C ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAG PROTEIN;

CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; LYMPHOCYTE COUNT; NONHUMAN; QUALITY CONTROL; QUANTITATIVE DIAGNOSIS; REVIEW; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0035156148     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/667G-UB9V-A78X-1RPP     Document Type: Review

References (80)

1. Markers predicting progression of human immunodeficiency virus-related disease
2. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
3. Plasma viremia in human immunodeficiency virus infection
4. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons
5. High-level viremia in adults and children infected with human immunodeficiency virus type 1 infection
6. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma
7. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay
8. Plasma HIV-1 viremia in HIV-1 infected individuals assessed by polymerase chain reaction
9. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR
10. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection
11. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection
12. Quantification of HIV-1 RNA in plasma using NASBA during primary infection
13. Gen-Probe single tube quantitative HIV assay
14. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C and D isolates from Kenya
15. Quantification of HIV-1 group M (subtypes A-G) and group O by the LCx HIV RNA quantitative assay
16. HIV viral load markers in clinical practice
17. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy
18. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
19. Viral dynamics in human immunodeficiency virus type 1 infection
20. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life span, and viral generation time
21. Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma
22. Comparison of the Amplicor HIV-1 Monitor test and the nucleic acid sequence-based amplification assay for quantitation of human immunodeficiency virus RNA in plasma, serum, and plasma subjected to freeze thaw cycles
23. Stability of human immunodeficiency virus RNA in blood specimens as measured by a commercial PCR-based assay
24. Effects of anticoagulant, processing delay, and assay method (branched DNA versus reverse transcription PCR) on measurement of human immunodeficiency virus type 1 RNA levels in plasma
25. Rapid and simple method for purification of nucleic acids
26. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 in plasma
27. Evaluation of the Abbott LCx HIV-1 RNA Quantitative, a new assay for quantitative determination of human immunodeficiency virus type 1 RNA
28. Comparison of levels of human immunodeficiency virus type 1 RNA in plasma as measured by the NucliSens nucleic acid sequence-based amplification and Quantiplex branched-DNA assays
29. Duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-l RNA at the nadir
30. Suppression of plasma viral load below 20 copies/mL is required to achieve long term response to therapy
31. Predictive value of the ultrasensitive HIV viral load assay in clinical practice
32. The impact of ultrasensitive HIV-1 RT-PCR assay on clinical decision making
33. Subtype-specific problems with quantification of plasma HIV-1 RNA
34. Comparison of branched DNA and reverse transcriptase polymerase chain reaction for quantifying six different HIV-1 subtypes in plasma
35. Reactivity and amplification efficiency of the NASBA HIV-1 RNA amplification system with regard to different HIV-1 subtypes
36. Comparison of three different commercial methods for measuring plasma viremia in patients infected with non-B HIV-1 subtypes
37. Impact of HIV-1 subtype variation on viral RNA quantitation
38. Design and evaluation of a human immunodeficiency virus type 1 RNA assay using nucleic acid sequence based amplification technology able to quantify both group M and O viruses by using the long terminal repeat as target
39. NucliSens EasyQ HIV-1: New high throughput assay for viral load measurements based on real time detection with molecular beacons
40. Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: Assessment of parameters affecting assay outcome
41. The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements
42. Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: Effect of an external standard on kit comparisons
43. Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved Amplicor HIV-1 Monitor test with isolates of diverse subtypes
44. Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests
45. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
46. Activation of virus replication after vaccination of HIV-1 infected individuals
47. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination
48. Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma
49. Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma
50. Intra-assay performance characteristics of five assays for quantification of human immunodeficiency virus type 1 RNA in plasma
51. Amplicor HIV Monitor, NASBA HIV-1 RNA QT and Quantiplex HIV RNA version 2.0 viral load assays: Canadian evaluation
52. Evaluation of three commercial procedures for quantifying human immunodeficiency virus type-1 RNA levels
53. Comparison of the Quantiplex version 3.0 assay and a sensitized Amplicor monitor assay for measurement of human immunodeficiency virus type-1 RNA levels in plasma samples
54. Comparison between a nucleic acid sequence-based amplification and branched DNA test for quantifying HIV RNA load in blood plasma
55. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion
56. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
57. The effect of maternal viral load on the risk of perinatal transmission of HIV-1
58. Viral load and heterosexual transmission of human immunodeficiency virus type 1
59. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: Effect of maternal zidovudine treatment on viral load
60. The influence of HIV shedding in the genital tract and mother-to-child transmission
61. Antiretroviral therapy and cesarean section to reduce vertical transmission of HIV in Europe
62. Antiretroviral resistance testing in HIV infected adults
63. Measuring HIV treatment adherence in clinical practice
64. Correlation between viral load measurements and outcome in clinical trials of antiviral drugs
65. False positive HIV diagnosis by HIV-1 plasma viral load testing
66. Diagnosis of acute HIV infection using p24 antigen and HIV-1 RNA assays
67. Pitfalls of HIV RNA testing in the San Francisco post-exposure prevention (PEP) project
68. HIV-1 RNA detection in plasma for the diagnosis of infection in neonates
69. Early detection of perinatal human immunodeficiency virus (HIV) type 1 infection using HIV RNA amplification and detection: New York City Perinatal HIV Transmission Collaborative Study
70. Comparison of human immunodeficiency virus 1 DNA polymerase chain reaction and qualitative and quantitative RNA polymerase chain reaction in human immunodeficiency virus 1-exposed infants
71. Marching toward single-donor NAT
72. Blood screening by nucleic acid amplification technology: Current issues, future challenges
73. CSF HIV-1 RNA quantitation as a prognostic marker for the differential diagnosis of AIDS related encephalopathy
74. Quantification of human immunodeficiency virus type 1 RNA from dried blood spots collected on filter paper
75. HIV infection of the central nervous system is characterized by rapid turnover of viral RNA in cerebrospinal fluid
76. Highly sensitive methods for quantitation of human immunodeficiency virus type 1 from plasma, cells, and tissues
77. Comparison of two amplification technologies for detection and quantitation of human immunodeficiency virus type 1 RNA in the female genital tract
78. Multicenter evaluation of methods to quantitate human immunodeficiency virus type 1 RNA in seminal plasma
79. Quantitation of human immunodeficiency virus type 1 RNA in different biological compartments